Peptide Comparison
SM-130686vsCJC-1295 with DAC
Experimental oral growth hormone secretagogue with anabolic potential from preclinical research
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
At a Glance
Quick
comparison
Dose Range
SM-130686
5–20 mg
CJC-1295 with DAC
1000–2000 mcg
Frequency
SM-130686
Multiple times daily
CJC-1295 with DAC
Twice weekly
Administration
SM-130686
Oral capsule or powder
CJC-1295 with DAC
Subcutaneous injection
Cycle Length
SM-130686
8-12 weeks
CJC-1295 with DAC
8-12 weeks
Onset Speed
SM-130686
Moderate (1-2 weeks)
CJC-1295 with DAC
Moderate (1-2 weeks)
Evidence Level
SM-130686
Moderate human trials (Phase 1-2)
CJC-1295 with DAC
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Muscle and Strength
Recovery and Performance
Metabolic Health
GH Elevation
Convenience
Recovery Support
Technical Data
Compound
specifications
SM-130686
Molecular Formula
C22H24Cl2F3N3O3
Molecular Weight
506.3 g/mol (as HCl salt)
Half-Life
Not published in humans (preclinical only)
Bioavailability
28% in rats (oral administration)
CAS Number
259667-25-9
CJC-1295 with DAC
Molecular Formula
C165H269N47O46
Molecular Weight
3647.28 g/mol
Half-Life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
SM-130686
CJC-1295 with DAC
Applications
Best
suited for
SM-130686
Lean Mass Building in Trained Athletes
SM-130686 targets GHS-R to stimulate GH release, which supports anabolic processes. Preclinical studies in rats showed significant increases in fat-free mass and body weight when combined with resistance training principles.
Age-Related GH Decline
As a GHS-R agonist, SM-130686 may help restore physiological GH secretion in adults experiencing age-related decline. The oral route is convenient for long-term administration.
Recovery and Performance
GH supports tissue repair, collagen synthesis, and recovery. May benefit individuals engaged in intensive resistance training or athletic performance work.
CJC-1295 with DAC
Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Safety Profile
Side
effects
SM-130686
Common
- Appetite stimulation
- Transient water retention
Uncommon
- Joint or muscle aches
- Transient changes in blood glucose
Serious
- Potential carpal tunnel syndrome
- Unknown effects on tumor growth
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Research Status
Safety
& evidence
SM-130686
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
SM-130686 is a research compound that has never been tested in humans. All safety and efficacy data come from animal studies (primarily rats). No human clinical trials have been conducted. Use carries unknown risks. Potential side effects based on GH physiology and limited preclinical work.
Contraindications
- xPregnancy or breastfeeding (no safety data)
- xActive cancer (GH stimulation may be contraindicated)
- xUncontrolled diabetes (may affect glucose metabolism)
- xSevere cardiovascular disease (GH effects on heart not fully characterized)
CJC-1295 with DAC
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- xActive cancer or history of malignancy
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xDiabetic retinopathy
- xUncontrolled diabetes
Decision Guide
Which is
right for you?
Choose SM-130686 if...
- Lean mass building (theoretical)
- Strength development (preclinical evidence)
- Body composition improvement (animal studies)
Choose CJC-1295 with DAC if...
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity